Back to Breast Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT01075802

NCT01075802
Completed Not Applicable 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You are generally able to carry out your normal daily activities with little or no limitation (confirm with trial site)
  • Your doctors expect you to live for at least 6 months or more
  • You have been diagnosed with breast cancer (either early stage, locally advanced, or spread to other parts of the body), confirmed by a lab test on a tissue or cell sample
  • Your breast cancer is fuelled by the hormone oestrogen (known as "oestrogen receptor positive")
  • You are about to start taking tamoxifen, or you are already taking tamoxifen at a dose of 20mg per day
  • Your liver and kidneys are working well enough to take part in the trial

Who may not be able to join:

  • You are currently receiving chemotherapy or radiotherapy
  • You are taking any medicines that may affect the way certain liver enzymes process drugs (confirm with trial site which medicines are affected)
  • You have a history of blood clots (thrombosis)
  • You have a history of not following treatment plans as prescribed in the past or currently
  • You have a medical or mental health condition that would make it difficult for you to fully understand and agree to take part in the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Trial details

Status
Completed
Phase
Not Applicable
Sponsor
Western Sydney Local Health District
Registry
clinicaltrials_gov
Start date
1 March 2010
Est. completion
1 October 2012

Where this trial is recruiting

🇦🇺 Australia

2 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Effects of genotype of CYP2D on plasma and serum concentration of tamoxifen and its metabolites, with consequent recommendation for dosage adjustment; To test whether Tamoxifen dose escalation in patients with genetic polymorphism of CYP2D6 will increase endoxifen blood levels to a target level; Correlate tamoxifen and its metabolites concentration with tamoxifen side effects

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov